دورية أكاديمية
أعرض في EDS

Associations of ITPA gene polymorphisms with outcomes among chronic hepatitis C patients treated with Peg-interferon/ribavirin: A 5-year follow-up study.

التفاصيل البيبلوغرافية
العنوان: Associations of ITPA gene polymorphisms with outcomes among chronic hepatitis C patients treated with Peg-interferon/ribavirin: A 5-year follow-up study.
المؤلفون: Liu Z; Department of Cardiovascular Medicine, The Third Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China., Wang Y; Department of Cardiovascular Medicine, The Third Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China., Li H; Department of Cardiovascular Medicine, The Third Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China., Wang X; Jilin Institute for Drug Control, Changchun, China., Wang X; College of Food Science and Engineering, Northwest A&F University, Yangling, Shanxi, PR China., Xu X; Huanan Agricultural Technology Extension Center, Huarong, China., Ma C; Sichuan Tianzow Breeding Co., Ltd, Chongqing, China., Wang J; Department of Digestive, China-Japan Union Hospital Affiliated to Jilin University, Changchun, China.
المصدر: Medicine [Medicine (Baltimore)] 2023 Oct 27; Vol. 102 (43), pp. e35508.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 2985248R Publication Model: Print Cited Medium: Internet ISSN: 1536-5964 (Electronic) Linking ISSN: 00257974 NLM ISO Abbreviation: Medicine (Baltimore) Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Hagerstown, Md : Lippincott Williams & Wilkins
مواضيع طبية MeSH: Ribavirin*/therapeutic use , Hepatitis C, Chronic*/drug therapy , Hepatitis C, Chronic*/genetics, Humans ; Antiviral Agents/therapeutic use ; Follow-Up Studies ; Treatment Outcome ; Pyrophosphatases/genetics ; Interferons/therapeutic use ; Polymorphism, Single Nucleotide ; Genotype ; Hepacivirus/genetics ; Liver Cirrhosis/drug therapy ; Liver Cirrhosis/genetics ; Liver Cirrhosis/chemically induced ; Interleukins/genetics ; Inosine Triphosphatase
مستخلص: To investigate associations between inosine triphosphatase (ITPA) gene polymorphisms and long-term outcomes among chronic hepatitis C (CHC) patients in Northeast China treated with Peg-interferon (IFN)/ribavirin (RBV). CHC patients who received Peg-IFN-2a/RBV treatment during between 2011 and 2013 at 5 hepatitis centers in Northeast China were enrolled. ITPA single nucleotide polymorphisms rs1127354 and rs7270101 from all patients were detected and their associations with 5-year outcomes were analyzed. A total of 635 patients, including 421 infected with hepatitis C virus (HCV) genotype 1 and 214 infected with non-genotype 1 were included. No significant differences were observed in the distribution frequencies of ITPA rs1127354 variants and ITPase activity between patients with HCV genotype 1 and non-genotype 1. In patients who received more than 80% of the planned RBV dose, the 5-year virological response rate and the improvement in liver fibrosis were higher in those with ITPA rs1127354 non-CC with ITPase activity <25% compared with these outcomes in patients with ITPA rs1127354 CC with 100% ITPase activity. Multiple regression analysis revealed that HCV genotype non-1, low baseline HCV ribose nucleic acid (RNA) levels (≤4 × 105 IU/mL), interleukin-28B rs12979860 CC genotype, low baseline liver fibrosis (Fibroscan 0-2), and ITPA rs1127354 non-CC genotype were independent predictors for a high long-term virological response rate, whereas interleukin-28B rs12979860 CC genotype, ITPA rs1127354 non-CC genotype, and low baseline liver fibrosis were independent predictors for improvement of liver fibrosis. ITPA rs1127354 polymorphisms is predictors of long-term outcomes in CHC patients treated with Peg-IFN/RBV.
Competing Interests: The authors have no funding and conflicts of interest to disclose.
(Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.)
References: Bierau J, Lindhout M, Bakker JA. Pharmacogenetic significance of inosine triphosphatase. Pharmacogenomics. 2007;8:1221–8.
Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–82.
Sumi S, Marinaki AM, Arenas M, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet. 2002;111:360–7.
Maeda T, Sumi S, Ueta A, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency in the Japanese population. Mol Genet Metab. 2005;85:271–9.
Shipkova M, Lorenz K, Oellerich M, et al. Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a Caucasian population. Clin Chem. 2006;52:240–7.
Sakamoto N, Tanaka Y, Nakagawa M, et al. ITPA gene variant protects against anemia induced by pegylated interferon-α and ribavirin therapy for Japanese patients with chronic hepatitis C. Hepatol Res. 2010;40:1063–71.
Kim JS, Ahn SM, Jung YK, et al. The impact of inosine triphosphatase variants on hemoglobin level and sustained virologic response of chronic hepatitis C in Korean. J Korean Med Sci. 2013;28:1213–9.
Thompson AJ, Fellay J, Patel K, et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology. 2010;139:1181–9.
Eskesen AN, Melum E, Moghaddam A, et al. Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort. Eur J Gastroenterol Hepatol. 2012;24:890–6.
Morio K, Imamura M, Kawakami Y, et al. ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C. J Gastroenterol. 2017;52:746–53.
Nakayama M, Kobayashi H, Fukushima K, et al. Predictive factors for 24 weeks sustained virologic response (SVR24) and viral relapse in patients treated with simeprevir plus peginterferon and ribavirin. Hepatol Int. 2016;10:158–68.
Rembeck K, Waldenström J, Hellstrand K, et al. Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3. Hepatology. 2014;59:2131–9.
Reig M, Mariño Z, Perelló C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65:719–26.
Strazzulla A, Iemmolo RMR, Carbone E, et al. The risk of hepatocellular carcinoma after directly acting antivirals for Hepatitis C virus treatment in liver transplanted patients: is it real? Hepat Mon. 2016;16:e41933.
Alberti A, Piovesan S. Increased incidence of liver cancer after successful DAA treatment of chronic hepatitis C: fact or fiction? Liver Int. 2017;37:802–8.
Bielen R, Moreno C, Van Vlierberghe H, et al. The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: a Belgian experience. J Viral Hepat. 2017;24:976–81.
Villani R, Facciorusso A, Bellanti F, et al. DAAs rapidly reduce inflammation but increase serum VEGF level: a rationale for tumor risk during anti-HCV treatment. PLoS One. 2016;11:e0167934.
Liu Z, Wang S, Qi W, et al. The relationship between ITPA rs1127354 polymorphisms and efficacy of antiviral treatment in Northeast Chinese CHC patients. Medicine (Baltim). 2017;96:e7554.
European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55:245–64.
European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63:199–236.
Abd-Elsalam S, Badawi R, Elnawasany S, et al. Sofosbuvir, pegylated interferon and ribavirin in the treatment of an Egyptian cohort with Hepatitis C virus infection in real-life clinical practice. Infect Disord Drug Targets. 2019;19:179–84.
Ahmed OA, Kaisar HH, Hawash N, et al. Efficacy of Sofosbuvir plus ribavirin with or without Peginterferon-Alfa in treatment of a cohort of Egyptian patients with hepatitis C virus infection. Infect Disord Drug Targets. 2017;17:95–100.
Elwan N, Amr K, Elyamany S, et al. Association of IL-12 B gene polymorphism with staging of liver disease in chronic HCV patients. Infect Disord Drug Targets. 2018;18:122–8.
Fellay J, Thompson AJ, Ge D, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature. 2010;464:405–8.
Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65:727–33.
المشرفين على المادة: 49717AWG6K (Ribavirin)
0 (Antiviral Agents)
EC 3.6.1.- (Pyrophosphatases)
9008-11-1 (Interferons)
0 (Interleukins)
EC 3.6.1.9 (ITPA protein, human)
تواريخ الأحداث: Date Created: 20231031 Date Completed: 20231102 Latest Revision: 20240208
رمز التحديث: 20240208
مُعرف محوري في PubMed: PMC10615403
DOI: 10.1097/MD.0000000000035508
PMID: 37904484
قاعدة البيانات: MEDLINE
الوصف
تدمد:1536-5964
DOI:10.1097/MD.0000000000035508